Journal of Oncology 2023

1 papers

Top Research Directions

The 5 research directions with Journal of Oncology 2023 papers, ranked by paper count, next to 2022. Share is the fraction of the edition’s papers in the direction.

#Direction20232022Share 2023Share 20222022 rank
1Molecular Biomarkers for Cancer Prognosis and Therapy Stratification10100.0%0.0%—
2Predictive Modeling with Public Cancer Genomics Data10100.0%0.0%—
3Prognostic Value Assessment via Cancer Survival Analysis10100.0%0.0%—
4Proteomic Biomarkers for Cancer Prognosis and Treatment Response10100.0%0.0%—
5Systemic Biases and Causal Limitations in Retrospective Studies12100.0%28.6%3

Download all directions as CSV

Institutions

Institutions credited by Journal of Oncology 2023 papers: a paper credits every institution named in its affiliations, once. 3 institutions share 1 credited papers.

#InstitutionPapersShare20222022 rank
104hb4m461 1100.0%0—
2053v2gh09 1100.0%0—
3Nanchang University 1100.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Oncology 2023 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2022 use shares, since the edition went from 7 to 1 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Oncology 2023”, https://lacuna.tiptreesystems.com/venue/journal-of-oncology/2023.

Papers

Title
The Upregulation of GSTO2 is Associated with Colon Cancer Progression and a Poor Prognosis